Hugh Johnson Advisors LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 59.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 4,701 shares of the company’s stock after acquiring an additional 1,755 shares during the period. Hugh Johnson Advisors LLC’s holdings in Novartis were worth $404,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Cetera Investment Advisers purchased a new stake in shares of Novartis during the 2nd quarter valued at about $241,000. Bartlett & Co. LLC increased its position in shares of Novartis by 1.6% during the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after purchasing an additional 7,249 shares during the last quarter. GFS Advisors LLC increased its position in shares of Novartis by 6.5% during the 2nd quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock valued at $1,779,000 after purchasing an additional 1,300 shares during the last quarter. Schafer Cullen Capital Management Inc. increased its position in shares of Novartis by 9.2% during the 2nd quarter. Schafer Cullen Capital Management Inc. now owns 2,780,606 shares of the company’s stock valued at $232,097,000 after purchasing an additional 233,292 shares during the last quarter. Finally, Union Bankshares Corp increased its position in shares of Novartis by 0.3% during the 2nd quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock valued at $3,132,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 10.87% of the company’s stock.
Shares of Novartis AG (NVS) traded down $1.04 on Wednesday, reaching $83.84. The company had a trading volume of 1,017,600 shares, compared to its average volume of 2,280,229. The company has a market capitalization of $200,791.69, a P/E ratio of 17.87, a PEG ratio of 2.71 and a beta of 0.73. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08.
NVS has been the subject of several research reports. Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Tuesday, September 19th. BidaskClub raised shares of Novartis from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Cowen set a $90.00 target price on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, August 9th. Leerink Swann increased their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis in a report on Tuesday, October 10th. Four analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $85.32.
ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/novartis-ag-nvs-stake-increased-by-hugh-johnson-advisors-llc.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.